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Abstract
Background: The small bowel (SB) represents the most important dose-limiting structure in pelvic radiotherapy (RT).
However, we observed that the majority of rectal cancer patients who received preoperative pelvic intensity
modulated RT (IMRT) developed acute tenesmus without watery diarrhea. The objective of this study is to determine
if the RT dose to SB affects the acute lower gastrointestinal toxicity (ALGIT) in rectal cancer patients who received
neoadjuvant concurrent chemotherapy-IMRT. We will also evaluate if patient and tumor factors affect the ALGIT.
Methods: We retrospectively analyzed 63 rectal cancer patients that consecutively received preoperative IMRT (45 Gy
for pelvis and 50 Gy for gross tumor in 25 fractions) with concurrent chemotherapy (oxaliplatin 130 mg/m2 on day 1 and
capecitabine 825 mg/m2, twice per day from day 1 to day 14, week 1 and 4) between May 2012 and May 2013. The ALGIT
was assessed with Common Terminology Criteria for Adverse Events version 3. The patients were stratified into two groups
(with and without grade ≥2 ALGIT). The effect of SB volume receiving 5 to 40 Gy (V5 to V40) at a 5 Gy interval dose level on
grade ≥2 ALGIT was evaluated. The volume of small bowel is defined as the volume of the small bowel loop. Other factors
evaluated include patient’s age and gender, tumor size and location and preexisting number of daily bowel movements.
Results: Overall, grade ≥2 ALGIT occurred in 57 % (36/63) patients. There was no significant difference between the two
groups of patients (with and without grade ≥2 ALGIT) in SB V5 to V40, patient’s age and gender, tumor location and
preexisting number of daily bowel movements. There was a significant difference between the two groups of patients in
tumor volume (with grade ≥2 ALGIT: 115.5 ± 85.5 cm3 versus without grade ≥2 ALGIT: 58.5 ± 25.2 cm3, p= 0.0001).
Multivariate analysis revealed no association between the dose SB received (V5 to V40) and the grade ≥2 ALGIT after
adjusting for the tumor volume.
Conclusions: With IMRT technique used in rectal cancer patients undergoing preoperative chemo-radiotherapy, the acute
lower GI toxicity is not associated with small bowel V5 to V40; instead it is associated with rectal tumor size.
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Introduction
Radiation therapy plays an important role in preopera-
tive and postoperative therapy for locally advanced rectal
cancer [1–4]. Radiation-induced lower GI toxicity is the
main concern. Serious acute lower GI toxicity was re-
ported in 12 to 44 % of patients undergoing radiotherapy
alone or with concurrent chemotherapy in multicenter
randomized clinical trials [4, 5]. The small bowel repre-
sents the most important dose-limiting structure in the
pelvic radiation therapy. Dosimetric studies revealed as-
sociation between the lower GI toxicity and the irradi-
ated small bowel volume [6, 7].
Since the German trial reported that preoperative
chemo-radiotherapy improved local control and was
associated with reduced toxicity as compared with post-
operative chemo-radiotherapy, preoperative concur-
rent chemo-radiotherapy has become a standard of care
for locally advanced rectal cancer (T3–4 and/or N posi-
tive) [4, 8]. A study has shown that the small bowel vol-
ume irradiated could be reduced in patients undergoing
preoperative radiotherapy as compared with those under-
going postoperative radiotherapy [9]. Intensity-modulated
radiation therapy (IMRT) has been confirmed to be advan-
tageous at protection of the organs at risk such as bladder,
femoral head and small bowel, and widely accepted as a
relatively safe and effective radiotherapy method in the
treatment of rectal cancer [10, 11]. Using IMRT technique
further decreases the small bowel in the radiation field as
compared to those using 3D conformal radiotherapy.
Hence, the acute lower GI toxicity could be decreased
significantly when IMRT used in preoperative chemo-
radiation therapy. In clinical practice, we noticed that most
rectal cancer patients who received preoperative IMRT
typically presented with tenesmus and a feeling of incom-
plete defecation without watery diarrhea and abdominal
pain. It seems that such side effects were induced rather
by rectal reaction to radiation than by small bowel
inflammation.
To better understand these clinical presentations, we
attempted to find out if the irradiated small bowel vol-
ume still is a predictor for acute lower GI toxicity during
preoperative concurrent chemo-radiotherapy for locally
advanced rectal cancer when IMRT is utilized. We also
examined other potential predictors for acute lower GI
toxicity in this patient population.
Patients and methods
Patient selection
The study population consisted of 63 patients with stage II
or III pathologically confirmed adenocarcinoma of the rec-
tum who were consecutively treated with preoperative
IMRT and concurrent chemotherapy between May 2012
and May 2013 in our hospital. The clinical stage and
the tumor location (distance from the anal edge) were
determined with physical examination and diagnostic stud-
ies, including digital rectal endoscopy, abdominal-pelvic
contrast-enhanced MRI, endorectal ultrasound (EUS) and a
chest CT scan. Factors recorded and analyzed include age,
gender, pre-treatment number of daily bowel movements
and number of daily bowel movements during the treat-
ment (see Table 1). The study was approved by the institu-
tional ethic committee (reference number: 2013KY011).
Radiotherapy
All patients underwent a contrasted CT simulation with a
supine position. Oral contrast was given 30 min prior to
simulation in order to differentiate the small bowel from
the large bowel. A planning CT scan of the lower abdo-
men and pelvis was obtained at 5-mm intervals from the
inferior edge of the second lumbar vertebrae (L2) through
the mid-thigh. The CT data was transferred to the Xio
treatment planning system (CMS Xio Version4.6 and
Table 1 Patient characteristics
n (%) Acute GI toxicity P value
N = 63 Grade < 2 Grade ≥2
N = 27 N = 36
Age (years)
Median (range) 55 (30–78) 55 (30–78) 57 (35–74)
Mean (SD) 56 (10) 55 (11) 57 (10) 0.388a
Gender
Male 45 (71.4) 16 29 0.092b
Female 18 (28.6) 11 7
T stage
T1 0 0 0 0.759b
T2 3 (4.8) 2 1
T3 33 (52.4) 14 19
T4 27 (42.8) 11 16
N stage
Negative 4 (6.3) 2 2 1.000b
Positive 59 (93.7) 25 34
Tumor volume (cc)
Median (range) 92 (20–318) 55 (20–135) 83 (26–318)
Mean (SD) 91 (72) 59 (25) 116 (86) 0.0004a
Tumor location (cm from the anal verge)
Median (range) 6 (2–12) 5 (3–10) 6(2–12)
Mean (SD) 6 (2) 6 (2) 6 (2) 0.738a
Pre-existing number of daily bowel movements
1 6 (9.5) 4 2 0.184b
2–3 25 (39.7) 13 12
4–6 25 (39.7) 9 16
≥ 7 7 (11.1) 1 6
aIndependent T test; bExact test
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Monaco 3.2.0, Elekta CMS Software, Maryland Heights,
MO) for delineating the target volume and organs at risk
(OARs).
The gross tumor volume (GTV) was contoured based
on clinical information, including digital rectal examin-
ation, endoscopy ultrasound and abdominopelvic MRI.
The clinical target volume (CTV) included a minimum of
a 3 cm craniocaudal margin to the GTV in addition to the
entire mesorectum, presacral, and internal iliac lymph
node drainage regions. The CTV was delineated per atlas
at the RTOG web site http://www.rtog.org/Corelab/
ContouringAtlases/Anorectal.aspx. Planning target vol-
umes (PTVs) for GTV and CTV were generated with an
additional 10-mm margin separately. Critical normal
structures including the small bowel, bladder, femoral
head, femoral neck, and pelvic bones (including sacrum,
ilium, pubis and ischium) were contoured according to
the pelvic normal tissue contouring guidelines of RTOG
[11, 12] . The small bowel was outlined as loops contain-
ing contrast. The small bowel contouring stopped at least
2 cm above the PTV-CTV (see Fig. 1a).
The IMRT plan consisted of 5 coplanar beams with
the isocenter set at the center of PTV-GTV, arranged at
55°, 115°, 180°, 245°and 310°. The dose prescribed to
PTV-GTV was 50 Gy/25fractions and to PTV-CTV was
45 Gy/25fractions. The doses to OARs were limited as
follows: V45 < 35 % for bladder, V30 < 15 % for femoral
head, and V30 < 60 % and Dmax <45 Gy for small bowel.
All patients were irradiated with one fraction daily for
five consecutive days per week. The prescription dose
was to cover at least 95 % volume of PTV.
A small bowel dose-volume histogram (DVH) was gen-
erated for each patient. The absolute and relative volumes
of small bowel receiving doses between 5 Gy and 40 Gy
were recorded from the DVH at 5-Gy interval (V5 to V40)
according to the study of Baglan KL [6].
Concurrent chemotherapy
The chemotherapy that patients received during the ra-
diation therapy was per an institutional protocol [13].
All patients had two 3-week cycles of chemotherapy dur-
ing the course of radiation therapy. The chemotherapy
regimen included oxaliplatin (130 mg/m2on day-1) and
capecitabine (825 mg/m2, twice per day from day-1 to
day-14) every 3 weeks.
Toxicity assessment
All patients received chemo-radiation therapy as inpa-
tients. The patients were evaluated and the toxicities were
recorded daily prospectively. For the purpose of this study,
the daily progress notes and the final treatment summary
note were reviewed to determine the lower GI toxicities
during the radiation therapy course. Lower GI toxicity was
assessed with Common Terminology Criteria for Adverse
Events (CTCAE) version 3. Because most patients had no
watery diarrhea or abdominal pain, we assessed the lower
GI toxicities by using only the number of daily bowel
movements [14] (see Table 2). Patients were stratified into
two groups: with grade <2 and grade ≥ 2 lower GI toxicity.
Statistical analysis
The chi-squared test was used to compare the propor-
tions of the two patient groups for the baseline patient
characteristics and RT delivery parameters. The inde-
pendent sample T-test was used to compare the treat-
ment target volume, small bowel volume, the volumes of
small bowel receiving doses between 5 Gy and 40 Gy be-
tween the two groups (patients with grade <2 and ≥ 2
lower GI toxicity). A p value of ≤ .05 was considered sig-
nificant. Statistical analyses were conducted using the
Statistical Analysis Systems software package, version 9.3
(SAS Institute, Cary, NC).
Results
Overall, acute grade ≥ 2 lower GI toxicity during radio-
therapy occurred in 57.1 % (36/63) patients. Among
them, 14 were grade 2, 22 grade 3 and 0 grade 4. Only 4
of 36 had watery diarrhea at the second, seventh, elev-
enth and sixteenth fraction of radiotherapy. The
remaining 27 patients experienced grade 0 and 1 lower
GI toxicities. The median age of the entire group of pa-
tients was 55 (range 30–78). Most patients were male
(71.4 %) and had a clinical stage of T3-4 (95.2 %) or
were N positive (93.7 %). The tumor located 2–12 cm
from the anal verge with a median of 6 cm. The tumor
volume ranged from 20 cm3 to 318 cm3 with a median
volume of 92 cm3 (Table 1). Patients with a larger tumor
volume had a significantly higher rate of grade ≥ 2 tox-
icity (59 ± 25 cm3 vs 116 ± 86 cm3, p = 0.0004). Almost
half of the patients (32/63) had pre-existing grade 2 or
above frequent bowel movements secondary to rectal
tumor (Table 1). It was found that 52.4 % (33/63) pa-
tients had either stable symptoms or had various extents
of improvement in symptoms during the radiotherapy.
The average total contoured small bowel volume for
all patients was 257 ± 152 cm3 and was 288 ± 193 cm3
and 234 ± 108 cm3 for patients that had lower GI toxic-
ities of grade < 2 and ≥ 2 (p = 0.244), respectively. Table 3
shows that small bowel V5 to V40 did not have signifi-
cant differences in patients with or without ≥ grade 2
acute lower GI toxicity.
Factors such as age, gender, T stage, N stage, tumor vol-
ume, tumor location, pre-existing number of daily bowel
movement and small bowel V5-V40 were analyzed in the
univariate logistic regression model (Table 4). All but
tumor volume (p = 0.002), pre-existing number of daily
bowel movements (p = 0.06) and gender (p = 0.07) were
not significantly correlated with grade ≥ 2 acute lower GI
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toxicity. Therefore, only tumor volume, pre-
existing number of daily bowel movements and gender
were included in the multivariate logistic regression
analysis. Multivariate analysis (Table 4) revealed that
tumor volume (OR 0.147, 95 % CI 0.043–0.499) and pre-
existing number of daily bowel movements (OR 0.272,
95 % CI 0.080–0.922) but not gender were significantly
correlated with grade ≥ 2 acute lower GI toxicity. Forcing
V5-V40 into the model showed that small bowel V5-V40
was not significantly correlated with grade ≥ 2 acute lower
GI toxicity.
Discussion
The most interesting finding of this study is no correla-
tions between the dose-volume parameters of small
bowel (V5 to V40) and the acute lower GI toxicity during
preoperative concurrent chemo-radiotherapy for rectal
cancer when IMRT is used. This study also revealed that
the rectal tumor volume is a predictor of grade ≥ 2 lower
GI toxicity. To our knowledge, this is the first study
to report that with IMRT, the acute lower GI toxicity
in this patient population is mainly influenced by rec-
tal tumor volume but not small bowel dose-volume
parameters.
Preoperative radiotherapy with IMRT decreased small
bowel volume in the pelvic radiation field
Minsky et al. showed a dramatic decrease of small bowel
volume in the radiation field for patients that received pre-
operative radiotherapy when compared with postoperative
radiotherapy (212 ± 44 cm3 versus 462 ± 129 cm3, p =
0.002) [9]. Sauer et al. found that ≥ grade 3 diarrhea
occurred in patients treated preoperatively significantly
less frequent than those treated postoperatively (12 % vs.
18 %, p = 0.04) [4]. To further reduce small bowel
volume in the radiation field, IMRT has been used in
several studies in the preoperative chemo-radiation ther-
apy for rectal cancer [15, 16]. Two dosimetric studies
showed that the small bowel volume was reduced signifi-
cantly in the radiation field with IMRT [17, 18]. In the
study by Arbea L et al., the small bowel V40 with IMRT
was only one third of the V40 treated with conventional
3-field technique (68.9 cc vs. 178.3 cc, p < 0.01) [19]. In
our study, all patients received preoperative radiotherapy
with IMRT technique. The small bowel V40 in the
current study was only 23–30 cc which is smaller than
the small bowl V40 (68.9 cc) in patients treated with
IMRT in the study of Arbea et al. Our study suggests
that the small bowel V5-V20 are no longer predictors for
grade ≥ 2 lower GI toxicity when an irradiated small bowl
volume is reduced to a very low level by using modern
radiotherapy technique such as IMRT.
Lower GI toxicity is the consequence of rectal irradiation
It is well known that the symptoms of small bowel and
rectal injury are different. The symptoms from acute
small bowel injury include watery diarrhea, colicky
abdominal pain, bloating, loss of appetite, nausea and de-
hydration [20]. On the other hand, the symptoms from
rectal injury typically include soft or diarrhea-like stools,
rectal pain and tenesmus (a sense of rectal distention
with cramping and frequency) [21]. Studies have shown
that patients treated with chemotherapy alone had a risk




1 Increase of <4 stools per day over pretreatment
2 Increase of 4–6 stools per day or nocturnal stools
3 Increase of ≥7 stools per day or incontinence or need
for parenteral support for dehydration
4 Physiologic consequences requiring intensive care of
hemodynamic collapse
(See figure on previous page.)
Fig. 1 a. Axial (left) and sagittal (right) views of small bowel contour in a 46 year-old male patient with a stage cT3 cN+ cM0 rectal cancer treated
with preoperative IMRT concurrent with chemotherapy. b. Reference video capsule endoscopy image for radiation induced small bowel injury:
Friability and oozing blood from atrophic-appearing mucosa. (Authorization by Medscape Drugs & Diseases). c. Case1: A 60 year-old female
patient with a stage cT3 cN+ cM0 rectal adenocarcinoma who presented with grade 2 tenesmus without watery stools on the day 13 of the
radiotherapy which was resolved in 2 days after symptomatic treatment. Video capsule endoscopy showed normal mucosa throughout the small
bowel. d. Case 2: A 60 year-old male patient with a stage cT2 cN+ cM0 rectal adenocarcinoma who did not experienced significant lower GI
toxicity during the treatment course. Video capsule endoscopy showed normal mucosa throughout the small bowel
Table 3 Comparison of small bowel dose-volume in patients
with grade < 2 to grade ≥2 acute lower GI toxicity
Dose level Small bowel volume(mean ± SD, cm3)
(Gy) Grade 0–1 Grade ≥2 P value
5 268 ± 173 217 ± 107 0.156
10 230 ± 154 189 ± 99 0.196
15 203 ± 138 169 ± 95 0.242
20 174 ± 124 143 ± 86 0.247
25 127 ± 105 103 ± 68 0.272
30 75 ± 78 60 ± 49 0.367
35 47 ± 63 37 ± 37 0.445
40 30 ± 49 23 ± 24 0.429
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of around 20 % in developing ≥ grade 3 treatment-related
diarrhea [22] and adding chemotherapy concurrently to
radiotherapy increased the frequency and severity of
diarrhea [23]. In theory, diarrhea caused by chemotherapy
should occur in the course of chemotherapy and could be
cured in a short duration. In our study, most patients
presented tenesmus. We believe that the occasional watery
diarrhea of 4 patients in our study was caused by concur-
rent chemotherapy since they only occurred during the
week of receiving chemotherapy and was cured in a week.
Primary tumor volume influences the lower GI toxicity
Another finding in this study was that the most common
acute lower GI toxicity was tenesmus. The gross tumor
volume was the only independent influencing factor for
the acute lower GI toxicity. The larger the tumor volume
the more frequent bowel movements (115.5 ± 85.5 cm3
versus 58.5 ± 25.2 cm3 for grade ≥ 2 and grade 0–1, p =
0.000). Given that most patients had no watery diarrhea,
we believe that the named lower GI acute toxicity is a
rectal reaction to the tumor and to the radiation injury. In
the study of Myerson RJ et al., although they used the
3D-CRT technique, they also found that proctitis was the
most common acute toxicity (5/37) during preoperative
chemo-radiotherapy and associated with large tumors
(PTV ≥ 500 cc). There was only one patient who had
enteritis during the treatment course [24].
Wireless whole gastrointestinal video capsule endoscopy
The acute toxicity of the small bowel is to a large extent
a result of clonogenic and apoptotic cell death in the
crypt epithelium, resulting in insufficient replacement of
the villus epithelium, breakdown of the mucosal barrier,
mucositis, and prominent compensatory and prolifera-
tive reactions (see Fig. 1b) [25]. The best way to observe
the small bowl reaction to radiation is to use the wireless
whole gastrointestinal video capsule endoscopy (VCE).
Video capsule endoscopy enables excellent visualization
of the small bowel mucosa [26]. Only a pilot study and a
case report demonstrated the usefulness of VCE for
radiation-induced late small bowel injury [27, 28]. We
elected 2 patients, one had grade 2 and the other had
grade 0 lower GI toxicity, to undergo VCE (Model of
JS-ME-II, Chongqing Jinshan Science and Technolgy
(group) Co.,Ltd) examination in 2 to 3 days after the
completion of preoperative chemo-radiotherapy in order
to observe the changes in the small bowel mucosa. The
Table 4 Factors associated with grade≥ 2 lower GI toxicity
Factors Median Univariate Multivariate
OR (95 % CL) P value OR (95 % CL) P value
Age (years) ≤55/>55 0.716 (0.259–1.946) 0.513
Gender Female/Male 0.351 (0.114–1.084) 0.069 0.376 0.108 1.308 0.124
T stage ≤ T3/>T3 0.859 (0.313–2.361) 0.769
N stage N-/N+ 0.735 (0.097–5.581) 0.766
Tumor volume (cc) ≤64/> 64 0.185 (0.062–0.550) 0.002 0.147 0.043 0.499 0.002
Tumor locationa ≤6/>6 0.700 (0.248–1.978) 0.501
Pre-existing BMb <4/≥ 4 0.374 (0.134–1.048) 0.061 0.272 0.080 0.922 0.036
Small bowel V5 (cc) ≤213/>213 1.562 (0.572–4.265) 0.384
Small bowel V10 (cc) ≤191/>191 1.562 (0.572–4.265) 0.384
Small bowel V15 (cc) ≤174/>174 1.818 (0.662–4.995) 0.246
Small bowel V20 (cc) ≤146/>146 1.818 (0.662–4.995) 0.246
Small bowel V25 (cc) ≤100/>100 1.626 (0.593–4.458) 0.345
Small bowel V30 (cc) ≤53/>53 1.818 (0.662–4.995) 0.246
Small bowel V35 (cc) ≤23/>23 0.550 (0.200–1.511) 0.246
Small bowel V40 (cc) ≤11/>11 0.640 (0.234–1.747) 0.384
aDistance from the anal verge; bpre-existing number of daily bowel movement
Table 5 Small bowel dose-volume for the two patients who
underwent VCE examination
Dose level Small bowel volume (cm3)
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duration of both VCE examinations were around 9 h and
both showed normal small bowel mucosa (see Fig. 1c and d).
The small bowel V5-V40 of these two patients are
shown in Table 5. These findings directly confirmed
our results that clinical lower GI toxicity in pelvic
IMRT is not associated with the dose-volume parame-
ters of small bowel.
Quantifying the lower GI toxicity
Although there were many reports concerning the acute
and chronic small bowel toxicity in pelvic radiation ther-
apy, little data has been published quantifying the details
of the toxicity such as extent, timing, duration, correl-
ation with chemotherapy, etc. It is very hard to evaluate
the lower GI toxicity via the status of stools for rectal
cancer, because for most patients, the most common
symptom at the time of diagnosis is increasing frequency
of stools with or without mixed blood. Among the 63
patients in our study, the number of pre-existing daily
bowel movements was found to be 1 time in 6 (9.5 %)
patients, 2–3 times in 25 (39.7 %) patient, 4–6 times in
25(39.7 %) patients and ≥ 7 stools in 7 patients (11.1 %)
(see Table 1). Almost half of these patients presented
with grade ≥ 2 bowel toxicity before initiating radiother-
apy treatment. Moreover, both RTOG [29] and CTCAE
[14] toxicity scales for lower GI toxicity are simple and
rapidly assessable, but provide limited information. For
example, they do not assess the development of anorec-
tal symptoms such as tenesmus which is the most com-
mon symptom during the pelvic irradiation, especially
for rectal cancer treated with IMRT technique. A modi-
fied questionnaire from the Inflammatory Bowel Disease
Questionnaire (IBDQ) and Vaizey Incontinence ques-
tionnaire may be more sensitive and useful for toxicity
data collection during the treatment and follow-up [30, 31].
Such questionnaires include much more information when
compared to RTOG and CTCAE scales.
Limitations of this study include its retrospective na-
ture, a lack of information on total small bowel volume
and details of toxicity.
Conclusion
When small bowel volume in the radiation field was
reduced to a low level with IMRT, it was no longer as
an influencing factor for acute lower GI toxicity. The
radiation-induced lower GI symptoms such as tenesmus
without watery diarrhea during pelvic IMRT may be
caused by the rectal tumor itself and rectal reaction to
radiotherapy. A future prospective study is warranted to
investigate the details of lower GI toxicity during treat-
ment and early follow-up, by using a real-time recorded
clinical note, modified questionnaire and whole gastro-
intestinal wireless capsule endoscopy.
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